BAYER stocks have experienced a significant drop with shares plummeting nearly 6%. The stock hit an 18-year low, this has been attributed to multiple issues including a court order to pay a substantial $2.25 billion in damages as well as the termination of the asundexian trial. Bayer shares were additionally affected by the cut in dividends, a decision made to tackle the company's mounting debt burden. Despite these setbacks, Bayer holds firm in its decision to focus on internal restructuring rather than facing a break-up. Major Bayer shareholder, Harris, supports this move. However, investors have expressed concerns over the need for a cash call due to the suffocating debt. Despite winning a reversal of $185 million PCBs verdict, more challenges lay ahead for Bayer. The stock of Metagenomi, backed by both Moderna and Bayer, experienced a notable drop on its Nasdaq debut. Despite these troubling times, Bayer's CEO rules out a capital increase and instead is shifting the focus onto self-management for employees along with a rigorous internal re-structuring plan. In the face of the increasing lawsuits over Roundup, Bayer is betting big on US appeals courts and weighing up 'Texas Two-Step' Bankruptcy Filing.
BAYER Stocks News Analytics from Tue, 25 Jul 2023 07:00:00 GMT to Wed, 08 May 2024 04:31:12 GMT -
Rating -8
- Innovation -3
- Information 8
- Rumor -5
